Benlysta Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving Benlysta Growth
1. Strong and Sustained Sales Growth Momentum
BENLYSTA generated ~USD 1.8 billion in 2025 sales (+22% YoY)
Earlier, global sales reached ~USD 3.47 billion in 2023 (+22% YoY)
Consistent double-digit growth trajectory reflects strong demand and market penetration
Positioned as a core growth driver within GlaxoSmithKline’s immunology portfolio
2. First-in-Class BLyS (BAFF) Inhibitor with Established Position
BENLYSTA is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS/BAFF), a key driver of B-cell survival in SLE.
It was the first approved biologic for SLE in >50 years, establishing strong physician familiarity
Mechanism supported by extensive clinical validation and long-term use
Entrenched position as standard-of-care biologic backbone in lupus
High switching barriers and brand loyalty
3. Expansion into Lupus Nephritis (Major Growth Driver)
Approved for lupus nephritis (LN)—a severe kidney manifestation of SLE
LN approval significantly broadened eligible patient population
LN represents a high-value, high-severity segment
Label expansion is a primary contributor to recent sales acceleration
4. Shift Toward Subcutaneous (SC) Self-Administration
Growth supported by subcutaneous formulation uptake, enabling at-home use
Widely adopted alongside IV formulation
Improves patient convenience and adherence
Expands use beyond infusion centers → broader access and volume growth
5. Increasing Adoption of Biologics in Lupus Treatment
Clinical practice is shifting from traditional immunosuppressants toward targeted biologics
BENLYSTA remains one of the most established biologics in SLE treatment algorithms
Structural shift in treatment paradigm supports long-term demand growth
Continued uptake in moderate–severe SLE patients
Benlysta Recent Developments
GSK has focused on increasing production capacity for Benlysta. In 2017, GSK invested $139 million in its Rockville, MD site to support the production of Benlysta, including the subcutaneous form.
“Benlysta Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Benlysta for approved indication like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis in the 7MM. A detailed picture of Benlysta’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Benlysta for approved and potential indications. The Benlysta market report provides insights about Benlysta’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Benlysta performance, future market assessments inclusive of the Benlysta market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Benlysta sales forecasts, along with factors driving its market.
Benlysta Drug Summary
Benlysta (Belimumab) is a recombinant human monoclonal antibody indicated for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis in patients receiving standard therapy. It specifically binds to and inhibits B-lymphocyte stimulator (BLyS, also known as BAFF), a cytokine that promotes the survival and differentiation of autoreactive B cells, thereby reducing abnormal B-cell activity and autoantibody production. Administered either as an intravenous infusion or subcutaneous injection, Benlysta has been shown in clinical trials to reduce disease activity, decrease flare rates, and improve renal outcomes in lupus nephritis. It is generally well tolerated, with common adverse effects including nausea, diarrhea, fever, and infusion-related reactions, although there is a potential risk of infections, hypersensitivity reactions, and neuropsychiatric events, requiring appropriate patient monitoring. The report provides Benlysta’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Benlysta Market Report
The report provides insights into:
A comprehensive product overview including the Benlysta MoA, description, dosage and administration, research and development activities in approved indications like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis.
Elaborated details on Benlysta regulatory milestones and other development activities have been provided in Benlysta market report.
The report also highlights Benlysta‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The Benlysta market report also covers the patents information, generic entry and impact on cost cut.
The Benlysta market report contains current and forecasted Benlysta sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Benlysta market report also features the SWOT analysis with analyst views for Benlysta in approved and potential indications.
Methodology
The Benlysta market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Benlysta Analytical Perspective by DelveInsight
In-depth Benlysta Market Assessment
This Benlysta sales market forecast report provides a detailed market assessment of Benlysta for approved indication like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Benlysta sales data uptil 2034.
Benlysta Clinical Assessment
The Benlysta market report provides the clinical trials information of Benlysta for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Benlysta Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Benlysta Market Potential & Revenue Forecast
Projected market size for the Benlysta and its key indications
Estimated Benlysta sales potential (Benlysta peak sales forecasts)
Benlysta Pricing strategies and reimbursement landscape
Benlysta Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Benlysta Market positioning compared to existing treatments
Benlysta Strengths & weaknesses relative to competitors
Benlysta Regulatory & Commercial Milestones
Benlysta Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Benlysta Clinical Differentiation
Benlysta Efficacy & safety advantages over existing drugs
Benlysta Unique selling points
Benlysta Market Report Highlights
In the coming years, the Benlysta market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Benlysta companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Benlysta’s dominance.
Other emerging products for Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis are expected to give tough market competition to Benlysta and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Benlysta in approved and potential indications.
Analyse Benlysta cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Benlysta sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Benlysta in approved and potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Benlysta? How strong is Benlysta’s clinical and commercial performance?
What is Benlysta’s clinical trial status in each individual indications such as Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Benlysta Manufacturers?
What are the key designations that have been granted to Benlysta for approved and potential indications? How are they going to impact Benlysta’s penetration in various geographies?
What is the current and forecasted Benlysta market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Benlysta in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Benlysta for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is Benlysta? What is the duration of therapy and what are the geographical variations in cost per patient?
1. Strong and Sustained Sales Growth Momentum
BENLYSTA generated ~USD 1.8 billion in 2025 sales (+22% YoY)
Earlier, global sales reached ~USD 3.47 billion in 2023 (+22% YoY)
Consistent double-digit growth trajectory reflects strong demand and market penetration
Positioned as a core growth driver within GlaxoSmithKline’s immunology portfolio
2. First-in-Class BLyS (BAFF) Inhibitor with Established Position
BENLYSTA is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS/BAFF), a key driver of B-cell survival in SLE.
It was the first approved biologic for SLE in >50 years, establishing strong physician familiarity
Mechanism supported by extensive clinical validation and long-term use
Entrenched position as standard-of-care biologic backbone in lupus
High switching barriers and brand loyalty
3. Expansion into Lupus Nephritis (Major Growth Driver)
Approved for lupus nephritis (LN)—a severe kidney manifestation of SLE
LN approval significantly broadened eligible patient population
LN represents a high-value, high-severity segment
Label expansion is a primary contributor to recent sales acceleration
4. Shift Toward Subcutaneous (SC) Self-Administration
Growth supported by subcutaneous formulation uptake, enabling at-home use
Widely adopted alongside IV formulation
Improves patient convenience and adherence
Expands use beyond infusion centers → broader access and volume growth
5. Increasing Adoption of Biologics in Lupus Treatment
Clinical practice is shifting from traditional immunosuppressants toward targeted biologics
BENLYSTA remains one of the most established biologics in SLE treatment algorithms
Structural shift in treatment paradigm supports long-term demand growth
Continued uptake in moderate–severe SLE patients
Benlysta Recent Developments
GSK has focused on increasing production capacity for Benlysta. In 2017, GSK invested $139 million in its Rockville, MD site to support the production of Benlysta, including the subcutaneous form.
“Benlysta Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Benlysta for approved indication like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis in the 7MM. A detailed picture of Benlysta’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Benlysta for approved and potential indications. The Benlysta market report provides insights about Benlysta’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Benlysta performance, future market assessments inclusive of the Benlysta market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Benlysta sales forecasts, along with factors driving its market.
Benlysta Drug Summary
Benlysta (Belimumab) is a recombinant human monoclonal antibody indicated for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis in patients receiving standard therapy. It specifically binds to and inhibits B-lymphocyte stimulator (BLyS, also known as BAFF), a cytokine that promotes the survival and differentiation of autoreactive B cells, thereby reducing abnormal B-cell activity and autoantibody production. Administered either as an intravenous infusion or subcutaneous injection, Benlysta has been shown in clinical trials to reduce disease activity, decrease flare rates, and improve renal outcomes in lupus nephritis. It is generally well tolerated, with common adverse effects including nausea, diarrhea, fever, and infusion-related reactions, although there is a potential risk of infections, hypersensitivity reactions, and neuropsychiatric events, requiring appropriate patient monitoring. The report provides Benlysta’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Benlysta Market Report
The report provides insights into:
A comprehensive product overview including the Benlysta MoA, description, dosage and administration, research and development activities in approved indications like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis.
Elaborated details on Benlysta regulatory milestones and other development activities have been provided in Benlysta market report.
The report also highlights Benlysta‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The Benlysta market report also covers the patents information, generic entry and impact on cost cut.
The Benlysta market report contains current and forecasted Benlysta sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Benlysta market report also features the SWOT analysis with analyst views for Benlysta in approved and potential indications.
Methodology
The Benlysta market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Benlysta Analytical Perspective by DelveInsight
In-depth Benlysta Market Assessment
This Benlysta sales market forecast report provides a detailed market assessment of Benlysta for approved indication like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Benlysta sales data uptil 2034.
Benlysta Clinical Assessment
The Benlysta market report provides the clinical trials information of Benlysta for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Benlysta Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Benlysta Market Potential & Revenue Forecast
Projected market size for the Benlysta and its key indications
Estimated Benlysta sales potential (Benlysta peak sales forecasts)
Benlysta Pricing strategies and reimbursement landscape
Benlysta Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Benlysta Market positioning compared to existing treatments
Benlysta Strengths & weaknesses relative to competitors
Benlysta Regulatory & Commercial Milestones
Benlysta Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Benlysta Clinical Differentiation
Benlysta Efficacy & safety advantages over existing drugs
Benlysta Unique selling points
Benlysta Market Report Highlights
In the coming years, the Benlysta market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Benlysta companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Benlysta’s dominance.
Other emerging products for Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis are expected to give tough market competition to Benlysta and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Benlysta in approved and potential indications.
Analyse Benlysta cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Benlysta sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Benlysta in approved and potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Benlysta? How strong is Benlysta’s clinical and commercial performance?
What is Benlysta’s clinical trial status in each individual indications such as Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Benlysta Manufacturers?
What are the key designations that have been granted to Benlysta for approved and potential indications? How are they going to impact Benlysta’s penetration in various geographies?
What is the current and forecasted Benlysta market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Benlysta in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Benlysta for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is Benlysta? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. Benlysta Overview in approved indications like Lupus nephritis and Systemic lupus erythematosus; as well as potential indication like Anti-neutrophil cytoplasmic antibody-associated vasculitis, Interstitial lung diseases, Myositis, Systemic scleroderma, Multiple sclerosis, and Myasthenia gravis
- 2.1. Product Detail
- 2.2. Benlysta Clinical Development
- 2.2.1. Benlysta Clinical studies
- 2.2.2. Benlysta Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. Benlysta Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging Benlysta Therapies)
- 5. Benlysta Market Assessment
- 5.1. Benlysta Market Outlook in approved and potential indications
- 5.2. 7MM Analysis
- 5.2.1. Benlysta Market Size in the 7MM for approved and potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. Benlysta Market Size in the United States for approved and potential indications
- 5.3.2. Benlysta Market Size in Germany for approved and potential indications
- 5.3.3. Benlysta Market Size in France for approved and potential indications
- 5.3.4. Benlysta Market Size in Italy for approved and potential indications
- 5.3.5. Benlysta Market Size in Spain for approved and potential indications
- 5.3.6. Benlysta Market Size in the United Kingdom for approved and potential indications
- 5.3.7. Benlysta Market Size in Japan for approved and potential indications
- 6. Benlysta SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
